Staphylococcus Or Streptococcus (e.g., Pneumococcus Or Streptococcus Pneumoniae, Streptococcus Mutans, Etc.) Patents (Class 424/165.1)
-
Publication number: 20130052204Abstract: Provided are an immunogenic composition comprising polyglycerol phosphate (PGP) and methods for using the composition for treating or preventing staphylococcal infections. The PGP may be conjugated to a T-cell dependent antigen. Also provided are methods for synthesizing PGP and methods for conjugating PGP to a T-cell dependent antigen.Type: ApplicationFiled: November 15, 2010Publication date: February 28, 2013Inventors: Clifford M. Snapper, Andrew Lees, James J. Mond, David Schwartz
-
Publication number: 20130045211Abstract: The present invention relates to methods and compositions for use in modulating, including inhibiting the growth and/or reducing the virulence of gram-positive bacteria. The present invention provides methods and compositions for disrupting the cell wall and/or cell membrane in gram-positive bacteria such that cell wall or cell membrane target(s) are rendered exposed or accessible and sensitive to a modulation thereof. Methods for modulation of one or more gram-positive bacterial cell wall or cell membrane targets in a gram-positive bacteria are provided comprising disrupting the cell wall such that the cell wall or cell membrane target, which is particularly a sortase, is rendered exposed or accessible and sensitive to a modifying, modulating or binding agent, which is particularly an antibody or fragment thereof, wherein the cell wall or cell membrane target is inaccessible or relatively insensitive to the modifying, modulating or binding agent in the absence of cell wall disruption.Type: ApplicationFiled: January 5, 2011Publication date: February 21, 2013Applicants: THE ROCKEFELLER UNIVERSITY, CONTRAFECT CORPORATIONInventors: Robert C. Nowinski, Vincent A. Fischetti, Assaf Raz
-
Patent number: 8377446Abstract: A newly identified serum resistance factor of gram positive bacteria can be used to treat or prevent bacterial infection.Type: GrantFiled: December 16, 2011Date of Patent: February 19, 2013Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Marco Soriani, Isabella Santi
-
Publication number: 20130017203Abstract: The present invention relates to methods and compositions for preventing and treating Staphylococcus aureus in a subject. Therapeutic compositions of the present invention comprise leukocidin E and/or D proteins or polypeptides and anti-leukocidin E and/or D antibodies. The invention further relates to methods of identifying inhibitors of LukE/D cytotoxicity and inhibitors of LukE/D-leukocyte binding.Type: ApplicationFiled: June 19, 2012Publication date: January 17, 2013Applicant: NEW YORK UNIVERSITYInventors: Victor J. TORRES, Francis ALONZO, III
-
Publication number: 20120322988Abstract: The present invention provides a therapeutic agent for psoriasis or atopic dermatitis, and comprises anti-Staphylococcus aureus antibodies as the active ingredient. A therapeutic agent for psoriasis or atopic dermatitis is specifically provided. This agent comprises comprehensive anti-S. aureus surface antibodies, including antibodies against entire cell-surface proteins, as the active ingredient. The agent is obtainable by: (a) treating S. aureus with a protein crosslinking/fixation reagent to fix proteins expressed on the surface of S. aureus via intramolecular crosslinking; (b) administering S. aureus treated with the protein crosslinking/fixation reagent for protein fixation to an animal as an immunogen; and (c) obtaining an antibody from the animal.Type: ApplicationFiled: November 12, 2010Publication date: December 20, 2012Inventor: Masayoshi Shichiri
-
Patent number: 8324354Abstract: The invention relates to the field of the diagnosis of and vaccination against Streptococcal infections, and to the detection of virulence markers of Streptococci. The invention discloses a method for modulating virulence of a Streptococcus comprising modifying a genomic fragment of the Streptococcus, wherein the genomic fragment comprises at least a functional part of a fragment identifiable by hybridization in Streptococcus suis to a nucleic acid or fragment thereof.Type: GrantFiled: October 31, 2007Date of Patent: December 4, 2012Assignee: Stichting Dienst Landbouwkundig OnderzoekInventor: Hilda Elizabeth Smith
-
Publication number: 20120301481Abstract: Immunogenic compositions and methods for eliciting an immune response against S. epidermidis and other related staphylococci are provided. The immunogenic compositions can include immunogenic conjugates of poly-?-glutamic acid (such as ?DLPGA) polypeptides of S. epidermidis, or related staphylococci that express a ?PGA polypeptide. The ?PGA conjugates elicit an effective immune response against S. epidermidis, or other staphylococci, in subjects to which the conjugates are administered. A method of treating an infection caused by a Staphylococcus organism that expresses cap genes is also disclosed. The method can include selecting a subject who is at risk of or has been diagonosed with the infection by the Staphylococcus organism which expresses ?PGA from the cap genes. Further, the expression of a ?PGA polypeptide by the organism can then be altered.Type: ApplicationFiled: July 20, 2012Publication date: November 29, 2012Inventors: Michael Otto, Stanislava Kocianova, Cuong Vuong, Jovanka Voyich, Yufeng Yao, Elizabeth Fischer, Frank De Leo
-
Patent number: 8241857Abstract: To provide an immunological detection method which can detect or quantify a pneumococcal antigen in a sample derived from a living body conveniently, rapidly, and with high sensitivity, and an antibody for use in the method. The present invention provides an antibody which specifically recognizes a pneumococcal F-antigen; a method for detecting or quantitating a pneumococcal antigen, characterized in that the method detects or quantitates a pneumococcal F-antigen in a sample derived from a living body through immunological assay employing the antibody; and a kit for detecting a pneumococcal antigen, the kit containing the antibody.Type: GrantFiled: March 31, 2009Date of Patent: August 14, 2012Assignee: Otsuka Pharmaceutical Co., Ltd.Inventors: Suguru Akamatsu, Yoko Saijo
-
Publication number: 20120201833Abstract: The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Some antibodies of the invention enhance opsonophagocytic killing and in vivo protection against bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.Type: ApplicationFiled: December 22, 2011Publication date: August 9, 2012Applicants: BETH ISRAEL DEACONESS MEDICAL CENTER, INC., THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Gerald B. Pier, Casie Anne Kelly-Quintos, Lisa Cavacini, Marshall R. Posner
-
Publication number: 20120201834Abstract: The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Some antibodies of the invention enhance opsonophagocytic killing and in vivo protection against bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.Type: ApplicationFiled: December 22, 2011Publication date: August 9, 2012Applicants: BETH ISRAEL DEACONESS MEDICAL CENTER, INC., THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Gerald B. Pier, Casie Anne Kelly-Quintos, Lisa Cavacini, Marshall R. Posner
-
Publication number: 20120195898Abstract: The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions.Type: ApplicationFiled: January 31, 2012Publication date: August 2, 2012Applicant: Epitopix, LLCInventors: Daryll A. Emery, Darren E. Straub
-
Publication number: 20120177650Abstract: A method and composition for treating enteric pathogen infections in animals suffering from such infections or displaying diseases or conditions consistent with such infections or for preventing or reducing the likelihood of enteric pathogen infections in animals at risk for developing such infections.Type: ApplicationFiled: September 22, 2010Publication date: July 12, 2012Inventor: Thomas Julius Borody
-
Publication number: 20120171223Abstract: This invention provides antibodies that specifically bind and neutralize Staphylococcus enterotoxin B. In addition, nucleic acids encoding such antibodies, and cells that express such antibodies are provided. Also provided are methods for treating diseases mediated by, and for neutralizing Staphylococcus enterotoxin B.Type: ApplicationFiled: January 3, 2008Publication date: July 5, 2012Inventors: Philip M. Sass, Nicholas C. Nicolaides, Luigi Grasso, Marc Berger, Tao Sai
-
Patent number: 8211431Abstract: The present invention provides human binding molecules specifically binding to staphylococci and having killing activity against staphylococci, nucleic acid molecules encoding the human binding molecules, compositions comprising the human binding molecules and methods of identifying or producing the human binding molecules. The human binding molecules can be used in the diagnosis, prophylaxis and/or treatment of a condition resulting from Staphylococcus.Type: GrantFiled: June 5, 2007Date of Patent: July 3, 2012Assignee: Crucell Holland B.V.Inventors: Mark Throsby, Cecilia A. W. Geuijen, Cornelis Adriaan De Kruif
-
Publication number: 20120148601Abstract: The present invention relates to genetically attenuated superantigen toxin vaccines altered such that superantigen attributes are absent, however the superantigen is effectively recognized and an appropriate immune response is produced. The attenuated superantigen toxins are shown to protect animals against challenge with wild type toxin. Methods of producing and using the altered superantigen toxins are described.Type: ApplicationFiled: November 28, 2011Publication date: June 14, 2012Inventors: ROBERT G. ULRICH, Mark A. Olson, Sina Bavari
-
Publication number: 20120107327Abstract: The present invention relates to immunogenic compositions, comprising polypeptides and polysaccharides from Staphylococcus aureus. The present invention also relates to immunogenic compositions, comprising Staphylococcus aureus capsule polysaccharides conjugated to a carrier protein. In addition, the invention relates to methods of inducing an immune response in subjects against Staphylococcus aureus using immunogenic compositions of the Staphylococcus aureus polypeptides and capsule polysaccharides.Type: ApplicationFiled: June 22, 2010Publication date: May 3, 2012Applicant: WYETH LLCInventors: Annaliesa Anderson, Viliam Pavliak, Kathrin Ute Jansen, Ingrid Lea Scully, Steven Morris Baker, Jasdeep Singh Nanra, Ellen Murphy, Bruce Arthur Green, Mark Edward Ruppen, Yekaterina Timofeyeva
-
Patent number: 8163288Abstract: The invention relates to antigenic polypeptides expressed by pathogenic microbes, vaccines comprising said polypeptides; therapeutic antibodies directed to said polypeptides and methods to manufacture said polypeptides, vaccines and antibodies.Type: GrantFiled: June 29, 2010Date of Patent: April 24, 2012Assignee: Absynth Biologics LimitedInventors: Simon J. Foster, Jorge Garcia-Lara
-
Publication number: 20120087930Abstract: The present invention relates to nucleic acids, vectors and polypeptides that are suitable markers for detecting Streptococcus strains of the anginosus group, preferably for detecting Streptococcus anginosus and/or Streptococcus constellatus as well as for discriminating Streptococcus anginosus and/or Streptococcus constellatus from other streptococci. The present invention furthermore relates to these nucleic acids and polypeptides for use in the diagnosis and/or prognosis of infections with Streptococcus strains of the anginosus group. The present invention furthermore relates to methods utilizing these nucleic acids and polypeptides as well as to arrays and antibodies.Type: ApplicationFiled: June 18, 2009Publication date: April 12, 2012Inventors: Gursharan S. Chhatwal, Patric Nitsche-Schmitz, Silvana Reissmann
-
Publication number: 20120082677Abstract: Therapeutic compositions for the treatment of viral hepatitis B (HBV) and hepatitis C (HCV) comprise antistreptokinase and antistreptolysine antibodies and/or tranexamic acid. Three antibodies against: polymerase, plasmin activators and fibrin are found in the blood of hepatitis C infected patients.Type: ApplicationFiled: October 1, 2010Publication date: April 5, 2012Inventor: Sherif Salah Abdul Aziz
-
Patent number: 8142780Abstract: A pharmaceutical composition includes a purified antibody and a pharmaceutically acceptable carrier. The antibody can be a monoclonal antibody having both an antigen-binding portion that binds at least one bacterial antigen and a constant region that does not bind staphylococcal protein A.Type: GrantFiled: August 31, 2010Date of Patent: March 27, 2012Assignee: STROX Biopharmaceuticals, LLCInventor: Stanley Arthur Kim
-
Publication number: 20120027771Abstract: The present invention discloses compositions and methods for treating, preventing and/or monitoring viral, bacterial, eukaryotic protist and/or fungal infections. In some embodiments, these compositions and methods involve human polyclonal antibodies affinity purified from human blood using certain viral, bacterial, eukaryotic protist and/or fungal antigens as described herein. Methods of making the antigenic preparations and the affinity-purified human polyclonal antibodies for passive immunization are also provided.Type: ApplicationFiled: April 12, 2011Publication date: February 2, 2012Inventor: THOMAS L. CANTOR
-
Publication number: 20110305688Abstract: The present invention provides proteins/genes, which are essential for survival, and consequently, for virulence of Streptococcus pneumoniae in vivo, and thus are ideal vaccine candidates for a vaccine preparation against pneumococcal infection. Further, also antibodies against said protein(s) are included in the invention.Type: ApplicationFiled: October 7, 2009Publication date: December 15, 2011Applicant: STICHTING KATHOLIEKE UNIVERSITEIT, MORE PARTICULARLY THE RADBOUD UNIVERISTY NIJMEGEN MEDICInventors: Peter Wilhelmus Maria Hermans, Hester Jeanette Bootsma, Pieter Jan Burghout, Christian Ostergaard Andersen, Oscar Paul Kuipers, Johanna Jacoba Elisabeth Bijlsma, Thomas Gerrit Kloosterman
-
Patent number: 8071102Abstract: Novel vaccines include polypeptides that comprise regions corresponding to a chemokine and a hapten. The hapten can be an amino acid sequence corresponding to the Meningitis Related Homologous Antigenic Sequences (MRHAS) of bacterial and viral agents known to cause meningitis. Protective immunity in a host susceptible to meningitis can be induced by inoculating the host with immunogenic amount of such a vaccine.Type: GrantFiled: January 24, 2000Date of Patent: December 6, 2011Inventors: Diane Van Alstyne, Lawrence R. Sharma
-
Publication number: 20110274700Abstract: The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Some antibodies of the invention enhance opsonophagocytic killing and in vivo protection against bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.Type: ApplicationFiled: May 9, 2011Publication date: November 10, 2011Applicants: BETH ISRAEL DEACONESS MEDICAL CENTER, INC., THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Gerald B. Pier, Casie Anne Kelly-Quintos, Lisa Cavacini, Marshall R. Posner
-
Publication number: 20110250202Abstract: The present invention provides PBP2a peptide antigens for generating antibodies against MRSA, and provides high-affinity binding agents that detect MRSA by selective immunoreactivity with PBP2a. The antibodies are useful in methods and systems for detecting MRSA, including biosensor systems, or as components of diagnostic or detection kits. The antibodies, in some embodiments, have therapeutic value against MRSA infection.Type: ApplicationFiled: May 7, 2009Publication date: October 13, 2011Applicant: Innovative Biosensors, Inc.Inventors: Colette Cote, Qiao-Xi Zheng, Venkatakrishna Shyamala, Tom Hazel
-
Publication number: 20110217312Abstract: Immunogenic compositions and methods for eliciting an immune response against S. epidermidis and other related staphylococci are provided. The immunogenic compositions can include immunogenic conjugates of poly-?-glutamic acid (such as ?DLPGA) polypeptides of S. epidermidis, or related staphylococci that express a ?PGA polypeptide. The ?PGA conjugates elicit an effective immune response against S. epidermidis, or other staphylococci, in subjects to which the conjugates are administered. A method of treating an infection caused by a Staphylococcus organism that expresses cap genes is also disclosed. The method can include selecting a subject who is at risk of or has been diagnosed with the infection by the Staphylococcus organism which expresses ?PGA from the cap genes. Further, the expression of a ?PGA polypeptide by the organism can then be altered.Type: ApplicationFiled: February 25, 2011Publication date: September 8, 2011Inventors: Michael Otto, Stanislava Kocianova, Cuong Vuong, Jovanka Voyich, Yufeng Yao, Elizabeth Fischer, Frank De Leo
-
Patent number: 8007803Abstract: The present invention provides isolated polypeptides isolatable from a Staphylococcus spp. Also provided by the present invention are compositions that include one or more of the polypeptides, and methods for making and methods for using the polypeptides.Type: GrantFiled: September 11, 2006Date of Patent: August 30, 2011Assignee: Epitopix, LLCInventors: Daryll A. Emery, Darren E. Straub, Laura Wonderling, Lisa L. Herron Olson
-
Publication number: 20110195075Abstract: Methods for enhancing opsonophagocytosis of a pathogen of interest are disclosed. The disclosed methods include administering to a subject an isolated P4 peptide, which including the amino acid sequence set forth as SEQ ID NO: 1 and optionally an isolated opsonic antibody or a fragment thereof that specifically binds to an antigen present of the surface of the pathogen of interest. In some examples isolated complement protein or a fragment thereof (for example, a C3a, C3b, iC3b, C3d, C4b, or C5a fragment of a complement protein) is also administering. Compositions contain isolated P4 peptide and one or more isolated opsonic antibodies or a fragment thereof that specifically binds to an antigen present of the surface of a pathogen of interest are also disclosed. In some examples, the compositions also isolated complement protein or fragment thereof, such as one or more of C3a, C3b, iC3b, C3d, C4b, or C5a.Type: ApplicationFiled: July 31, 2009Publication date: August 11, 2011Inventors: Edwin W. Ades, Gowrisankar Rajam, Sandra Steiner, George M. Carlone, Nikkol Melnick, Jacquelyn S. Sampson, Joseph E. Martinez, Julie M. Skinner
-
Publication number: 20110171224Abstract: Disclosed are pharmaceutical compositions that include a PsrP polypeptide, a nucleic acid encoding a PsrP polypeptide, or an antibody or fragment thereof that binds to a PsrP polypeptide domain, and methods of inhibiting, modulating, treating, or preventing a bacterial infection, such as an infection due to Streptococcus pneumoniae, in a subject using these compositions.Type: ApplicationFiled: May 22, 2009Publication date: July 14, 2011Inventor: Carlos J. Orihuela
-
Publication number: 20110171237Abstract: The present invention relates to antigenic polypeptides expressed by pathogenic microbes, including antigenic polypeptides encoded by the nucleic acid sequence of FIG. 1, vaccines comprising the antigenic polypeptides and therapeutic antibodies directed to the antigenic polypeptides.Type: ApplicationFiled: April 23, 2010Publication date: July 14, 2011Applicant: ABSYNTH BIOLOGICS LTD.Inventor: Simon J. FOSTER
-
Publication number: 20110091480Abstract: The present invention features antigen binding protein that bind an ORF0657n target region (SEQ ID NO: 1). ORF0657n is an S. aureus protein. ORF0657n target regions are provided by the mAb 1G3.BD4, mAb 2H2.BE11, mAb 13C7.BC1, and mAb 13G11.BF3 binding sites. In a lethal model challenge, mAb 2H2.BE11 and mAb 13C7.BC1 provided for increased survival against S. aureus infection. There was also protection demonstrated in an ex vivo model with either the IgG1 or the IgG2b form of mAb 2H2; and in a passive immunization murine indwelling catheter model using mAb 2H2.BE11.Type: ApplicationFiled: January 23, 2007Publication date: April 21, 2011Inventors: Martha J. Brown, Annaliesa S. Anderson, Leslie D. Cope, Kathrin Ute Jansen, Tessie McNeely, Barrett R. Harvey, Eberhard Durr, Robin Ernst
-
Patent number: 7927607Abstract: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from S. agalactiae, and methods for isolating such antigens and specific uses thereof.Type: GrantFiled: September 3, 2008Date of Patent: April 19, 2011Assignee: Intercell AGInventors: Andreas Meinke, Eszter Nagy, Markus Hanner, Markus Horky, Sabine Kallenda, Sonja Prustomersky
-
Patent number: 7927605Abstract: The invention relates to the field of the diagnosis of and vaccination against Streptococcal infections, and to the detection of virulence markers of Streptococci. The invention discloses a method for modulating virulence of a Streptococcus comprising modifying a genomic fragment of the Streptococcus, wherein the genomic fragment comprises at least a functional part of a fragment identifiable by hybridization in Streptococcus suis to a nucleic acid or fragment thereof.Type: GrantFiled: July 31, 2003Date of Patent: April 19, 2011Assignee: Stichting Dienst Landbouwkundig OnderzoekInventor: Hilda Elizabeth Smith
-
Publication number: 20110081347Abstract: This invention relates to antibodies with altered binding to FcRn, and particularly antibodies having enhanced binding to FcRn and/or enhanced serum half-lives. The invention also relates to methods of using the antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease.Type: ApplicationFiled: June 4, 2009Publication date: April 7, 2011Applicant: MacroGenics, Inc.Inventor: Sergey Gorlatov
-
Publication number: 20110064745Abstract: The present invention provides compositions, including pharmaceutical compositions, comprising an amount of an antibody, antibody fragment or antibody conjugate sufficient to treat Group A streptococcus (GAS) infection or complication thereof in a subject or a disease or complication associated with GAS infection in a subject wherein said antibody, antibody fragment or antibody conjugate binds immunospecifically to a B-cell epitope of GAS M-protein. The present invention also provides methods for the prophylactic or therapeutic treatment of infection by GAS and complications thereof comprising administering the compositions to a subject in need thereof.Type: ApplicationFiled: August 23, 2010Publication date: March 17, 2011Inventors: Michael F. Good, Michael R. Batzloff, Manisha Pandey
-
Publication number: 20110059085Abstract: A new antibody-based strategy for treating or preventing Staphylococcus aureus infections utilizes IgM antibodies specific for one or more Staphylococcus aureus capsular antigens. Examples of such antibodies include (i) a polyclonal IgM antibody composition that is isolated from pooled donor plasma and enriched for those IgMs that specifically bind Staphylococcus aureus capsular antigens or (ii) one or more IgM monoclonal antibodies that specifically bind Staphylococcus aureus capsular antigens.Type: ApplicationFiled: November 11, 2010Publication date: March 10, 2011Applicant: STROX BIOPHARMACEUTICALS, LLCInventor: Stanley A. Kim
-
Patent number: 7892552Abstract: This invention provides isolated nucleic acids encoding polypeptides comprising amino acid sequences of streptococcal matrix adhesion (Ema) polypeptides. The invention provides nucleic acids encoding Group B streptococcal Ema polypeptides EmaA, EmaB, EmaC, EmaD and EmaE. The present invention provides isolated polypeptides comprising amino acid sequences of Group B streptococcal polypeptides EmaA, EmaB, EmaC, EmaD and EmaE, including analogs, variants, mutants, derivatives and fragments thereof. Ema homologous polypeptides from additional bacterial species, including S. pneumoniae, S. pyogenes, E. faecalis and C. diptheriae are also provided. Antibodies to the Ema polypeptides and immunogenic fragments thereof are also provided. The present invention relates to the identification and prevention of infections by virulent forms of streptococci.Type: GrantFiled: December 7, 2009Date of Patent: February 22, 2011Assignees: University of Utah Research Foundation, St. Jude Children's Research HospitalInventors: Elisabeth Adderson, John Bohnsack
-
Publication number: 20110038879Abstract: Compositions for preventing and/or treating S. pyogenes infection which comprise one or more active agents. The active agents are SLO antigens, nucleic acid molecules encoding the SLO antigens, and/or antibodies which selectively bind to the SLO antigens.Type: ApplicationFiled: October 30, 2007Publication date: February 17, 2011Applicant: NOVARTIS AGInventors: Maria Scarselli, Giuliano Bensi, Guido Grandi
-
Publication number: 20110033479Abstract: The present invention relates to autoantigens selected from Ezrin, Serpin B5, Peroxiredoxin-2, heat shock protein ?1, and/or peptides comprising at least 5 consecutive amino acid residues of one of these autoantigenic proteins having immunological activity, or fragments, variants, or epitopes thereof and/or mixtures of at least two of the proteins and/or peptides as diagnostic tool for the detection of streptococcal driven conditions or as therapeutical agent for the treatment of streptococcal driven conditions.Type: ApplicationFiled: September 29, 2008Publication date: February 10, 2011Applicant: LUDWIG-MAXIMILIANS-UNIVERSITATInventors: Jörg C. Prinz, Petra Besgen, Paul Trommler
-
Publication number: 20110027265Abstract: Embodiments of the invention include methods and compositions useful in a vaccination strategy capable of neutralizing HIa to provide immunoprotection against S. aureus pneumonia. In certain aspects the invention includes a HIa with reduced toxicity, represented by a recombinant mutant form of HIa (HlaH35L) in which histidine 35 is converted to leucine, which can be used to abrogate the productive assembly of the toxin and protect a subject from staphylococcal pneumonia.Type: ApplicationFiled: August 29, 2008Publication date: February 3, 2011Applicant: The University of ChicagoInventors: Juliane Bubeck-Wardenburg, Olaf Schneewind, Brook Ragle
-
Publication number: 20110020216Abstract: A device that includes a scaffold composition and a bioactive composition with the bioactive composition being incorporated therein or thereon, or diffusing from the scaffold composition such that the scaffold composition and/or a bioactive composition captures and eliminates undesirable cells from the body a mammalian subject. The devices mediate active recruitment, sequestration, and removal or elimination of undesirable cells from their host.Type: ApplicationFiled: June 11, 2008Publication date: January 27, 2011Inventors: David James Mooney, Omar abdel-Rahman Ali
-
Patent number: 7867501Abstract: The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.Type: GrantFiled: September 21, 2006Date of Patent: January 11, 2011Assignee: Sanofi Pasteur Limited/Sanofi Pasteur LimiteeInventors: Lynn Doucette-Stamm, David Bush, Oiandong Zeng, Timothy Opperman, Chad Eric Houseweart
-
Publication number: 20100291177Abstract: The present application discloses antibodies directed to protein SE2232 (SesC) of Staphylococcus epidermis, and homologus proteins which are useful in preventing biofilm formation by said micro-organism. The antibodies can be used to coat medical devices which are inserted or implanted into the mammalian, preferably human body. Further these antibodies or vaccines comprising said proteins can be used to vaccinate subjects to prevent or treat natural occurring biofilm formation during infection. Also covered are medical devices coated with the antibody.Type: ApplicationFiled: April 11, 2008Publication date: November 18, 2010Inventors: Peter Wilhelmus Maria Hermans, Johan Van Eldere
-
Publication number: 20100278819Abstract: Streptococcus pneumoniae is a major cause of pneumoniae, meningitis, and major cause of morbidity and mortality throughout the world by bacterial otitis media, pneumoniae, meningitis, and bacteraemia. It is an important agent of disease in man especially among infants, the elderly and immunocompromised persons. The present invention provides a solution to this problem by providing a substantially pure or isolated disease related antigen selected from the group consisting of the isolated, recombinant or synthetic S. pneumoniae human immunogenic antigens of SP_0562, SP_0965, SP_0082 (in particular the fragments SP4 and SP 17 of said SP_0082), and a Periplasmic Binding Protein (PBP) (in particular SP_1683 or SP_1386), or a fragments thereof or substantially identical antigen for use in a treatment to induce a immunological memory in a human against S. pneumoniae cells for use in a vaccination treatment of S. pneumoniae disorder in human or against S. pneumoniae in a human.Type: ApplicationFiled: September 15, 2008Publication date: November 4, 2010Applicant: KATHOLIEKE UNIVERSITEIT LEUVENInventors: Xavier Bossuyt, Leen Moens
-
Publication number: 20100233185Abstract: Provided are methods, test devices, and diagnostic kits for predicting, assessing, and diagnosing the risk of a disease using salivary analysis. The methods comprise providing a whole (unfractionated) saliva sample from a subject; contacting an aliquot of the saliva with two or more lectins under conditions that allow the two or more lectins to bind to a lectin-binding component of the saliva; detecting the amount of bound lectin; and comparing the amount of bound lectin to the amount known to bind a saliva sample from a control patient, to predict the risk of a disease in the subject. Also provided are methods for reducing the risk of a disease and a method for assessing the risk of the disease at a defined level.Type: ApplicationFiled: May 24, 2010Publication date: September 16, 2010Inventors: Patricia Denny, Paul C. Denny, Mahvash Navazesh
-
Publication number: 20100196379Abstract: This invention provides isolated nucleic acids encoding polypeptides comprising amino acid sequences of streptococcal matrix adhesion (Ema) polypeptides. The invention provides nucleic acids encoding Group B streptococcal Ema polypeptides EmaA, EmaB, EmaC, EmaD and EmaE. The present invention provides isolated polypeptides comprising amino acid sequences of Group B streptococcal polypeptides EmaA, EmaB, EmaC, EmaD and EmaE, including analogs, variants, mutants, derivatives and fragments thereof. Ema homologous polypeptides from additional bacterial species, including S. pneumoniae, S. pyogenes, E. faecalis and C. diptheriae are also provided. Antibodies to the Ema polypeptides and immunogenic fragments thereof are also provided. The present invention relates to the identification and prevention of infections by virulent forms of streptococci.Type: ApplicationFiled: December 7, 2009Publication date: August 5, 2010Inventors: Elisabeth Adderson, John Bohnsack
-
Publication number: 20100166772Abstract: The present invention features antigen binding proteins that bind to a region found to have an epitope that can be targeted to provide protection against S. aureus infection. The region is designated herein as the “CS-D7” target region. The CS-D7 target region provides an S. aureus ORF0657n epitope that can be targeted to reduce the likelihood or severity of an S. aureus infection.Type: ApplicationFiled: May 29, 2008Publication date: July 1, 2010Inventors: Annaliesa S. Anderson, Desmond J. Clark, Zhiqiang An, Fubao Wang, Susan L. Secore, Eberhard Durr, Leslie D. Cope, Tessie McNeely
-
Publication number: 20100166732Abstract: The present invention relates to a peptide consisting of one antigen of Streptococcus pyogenes (S. pyogenes) of any of the SEQ ID NOS: 1 to 7 or a functional active variant thereof, optionally further consisting of additional amino acid residue(s); a nucleic acid coding for the same; a pharmaceutical composition, especially a vaccine, comprising said peptide or said nucleic acid; an antibody or functional active fragment thereof specifically binding to the antigen; a hybridoma cell line which produces said antibody; a method for producing said antibody; a pharmaceutical composition comprising said antibody; the use of said peptide or said nucleic acid for the manufacture of a medicament for the immunization or treatment of a subject; the use of said antibody or functional fragment thereof for the manufacture of a medicament for the treatment of an infection; a method of diagnosing a S.Type: ApplicationFiled: July 6, 2007Publication date: July 1, 2010Applicant: Intercell AGInventors: Andreas Meinke, Eszter Nagy, Alexander von Gabain, Manfred Berger, Beatrice Senn, Michael Schunn
-
Publication number: 20100150943Abstract: The invention relates to the identification of a new adhesin islands within the genomes of several Gram positive Streptococcus serotypes and isolates. Adhesin island polypeptides of the invention may be used in immunogenic compositions for prophylactic or therapeutic immunization against GAS, GBS, and S. pneumococcal infections.Type: ApplicationFiled: July 26, 2007Publication date: June 17, 2010Applicant: NOVARTIS AGInventors: Guido Grandi, John Telford, Marirosa Mora, Cesira Galeotti, Daniela Rinaudo, Andrea Guido Oreste Manetti
-
Publication number: 20100092487Abstract: According to the present invention, an antibody against a Panton-Valentine leukocidin toxin contained in Staphylococcus aureus, a method and a kit for detecting the toxin with the use of the antibody, and a pharmaceutical composition containing an antibody against a Panton-Valentine leukocidin toxin for treating PVL infection caused by Staphylococcus aureus containing PVL are provided. Also, an antibody which is capable of binding to Panton-Valentine leukocidin F and has no cross-reactivity to LukD and/or HlgB and an antibody which is capable of binding to Panton-Valentine leukocidin S and has no cross-reactivity to at least one of LukE, HlgC, and HlgA are provided.Type: ApplicationFiled: July 3, 2007Publication date: April 15, 2010Applicants: JUNTENDO UNIVERSITY SCHOOL OF MEDICINE, DENKA SEIKEN CO., LTD.Inventors: Kanenari Ohishi, Tadashi Baba, Keiichi Hiramatsu, Yasuo Nakatomi